Heliyon 8 (2022) e09736

Contents lists available at ScienceDirect

Heliyon

journal homepage: www.cell.com/heliyon

Research article

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils



Hiroshi Ohnishi^{a,*}, Masamitsu Eitoku^b, Akihito Yokoyama^a

^a Department of Respiratory Medicine and Allergology, Oko-cho, Kohasu, Nankoku, Kochi, 780-8505, Japan
^b Department of Environmental Medicine, Kochi Medical School, Kochi University, Oko-cho, Kohasu, Nankoku, Kochi, 780-8505, Japan

HIGHLIGHTS

• This integrated analysis shows limited efficacy of anti-IL-5 therapy in COPD.

• High doses of anti-IL-5 therapy are required to reduce moderate-to-severe exacerbations.

ARTICLE INFO

Keywords: Benralizumab Chronic obstructive pulmonary disease Eosinophil Exacerbation Mepolizumab

ABSTRACT

Background and aims: Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive pulmonary disease (COPD) patients with increased peripheral blood eosinophils. *Methods*: Clinical trials of biologics that target Type 2 inflammation in COPD were found using PubMed, the Cochrane Library, and ClinicalTrials.gov. We analyzed the clinical efficacy of anti-IL-5-targeted therapy at approved (benralizumab 30 mg, mepolizumab 100 mg, for severe asthma) and high (benralizumab 100 mg, mepolizumab 300 mg) doses. *Results*: Approved benralizumab and mepolizumab doses tended to reduce moderate-to-severe exacerbations by 9% [risk ratio (RR) 0.91, 95% confidence interval (CI) [0.83, 1.00], p = 0.05], but did not reduce exacerbations requiring emergency department visits or hospitalization. High-dose benralizumab and mepolizumab reduced moderate-to-severe exacerbations by 12% (RR = 0.88, 95% CI [0.80, 0.98], p = 0.02) and exacerbations requiring emergency department visits or hospitalization by 33% (RR = 0.67, 95% CI [0.53, 0.84], p = 0.0005). Neither dose improved St. George's Respiratory Questionnaire or COPD Assessment Test scores. The safety of benralizumab and mepolizumab to placebo.

Conclusions: Benralizumab and mepolizumab have limited efficacy in reducing moderate-to-severe exacerbations in COPD patients with increased peripheral blood eosinophils and requires at least high doses.

1. Introduction

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation. COPD is caused by airway and/or alveolar abnormalities following exposure to noxious particles such as tobacco smoke [1]. COPD exacerbation is defined as acute worsening of respiratory symptoms such as dyspnea, cough, and/or sputum that requires additional treatment including antibiotics, bronchodilator, and/or systemic corticosteroids; it accounts for a large proportion of the total COPD burden on healthcare costs [1]. A history of two or more exacerbations within the previous year is associated with deteriorating airflow limitation, the future development of exacerbations, hospitalization, poor prognosis, and an increased risk of death [1]. Therefore, a reduction in exacerbations was set as a primary outcome of clinical trials for the efficacy of anti-inflammatory drugs in COPD patients.

Type 2 airway inflammation induced by antigen-specific immunoglobulin E (IgE), interleukin-4 (IL-4), IL-5, IL-13, and thymic stromal lymphopoietin is associated with increased exacerbations and airway remodeling in patients with asthma. Omalizumab, dupilumab, benralizumab, and mepolizumab are monoclonal antibodies (mAbs) against IgE, IL-4/IL-13 signaling, the anti-IL-5 receptor α , and anti-IL-5,

* Corresponding author.

E-mail address: honi@kochi-u.ac.jp (H. Ohnishi).

https://doi.org/10.1016/j.heliyon.2022.e09736

Received 15 May 2022; Received in revised form 9 June 2022; Accepted 13 June 2022

2405-8440/© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).





respectively. In phase III clinical trials, these four mAbs reduced moderate-to-severe exacerbations in severe asthma patients with Type 2 airway inflammation [2, 3, 4, 5, 6] and are approved to treat severe asthma in Europe, the United States, and Japan. Recently, several biologics were tested in clinical trials for COPD [7, 8, 9, 10, 11], and five systematic reviews and meta-analyses evaluated the efficacy of biologics including benralizumab and mepolizumab on COPD patients [12, 13, 14, 15, 16]. However, these reports had some statistical problems, and/or compared their efficacy of biologics that target Type 2 inflammation should be investigated in COPD patients with Type 2 inflammation. Therefore, we conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in COPD patients with increased peripheral blood eosinophils.

2. Methods

2.1. Literature search

This systematic review and integrated analysis was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) Statement [17]. We searched for clinical trials of mAbs that target Type 2 inflammation, including omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, lebrikizumab, tralokinumab, and tezepelumab using the following medical subject heading terms "chronic obstructive pulmonary disease" and/or "COPD" in the PubMed, Cochrane Library, and ClinicalTrials.gov databases on 1 December, 2021.

2.2. Inclusion and exclusion criteria

Double-blind, placebo-controlled trials of these mAbs in study subjects with COPD were included. Subjects with asthma COPD overlap (ACO) were excluded. Two reviewers independently validated the relevant studies from the literature searches. The eligible studies were selected by PRISMA criteria and the disagreements regarding eligibility were resolved by consensus. The quality of a body of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system [18].

2.3. Outcome measures

The following outcome measures were included to evaluate clinical efficacy and safety: moderate-to-severe exacerbations, time to the first moderate-to-severe exacerbation, exacerbations leading to an emergency department (ED) visit or hospitalization, the St. George's Respiratory Questionnaire (SGRQ) score, COPD Assessment Test (CAT) score, prebronchodilator forced expiratory volume in one second (FEV1), rescue inhaler use, the proportion of nights awoken, all adverse events, serious adverse events, and death. The effect measures used in the outcome synthesis are as follows. The risk ratio (RR) was used for moderate-to-severe exacerbations and exacerbations leading to an ED visit or hospitalization. The hazard ratio (HR) was used for time to first moderate-to-severe exacerbation. The mean difference (MD) was used for the SGRQ score, the CAT score, FEV1, rescue inhaler use, and the proportion of nights awoken. The odds ratio (OR) was used for all adverse events, serious adverse events, and death.

2.4. Statistical analysis

The integrated analysis was conducted with the "meta" package of R version 4.1.1. A *p*-value less than 0.05 was considered statistically significant. Statistical heterogeneity among the trials was assessed using the standard I^2 value of 0–25%, 25–50%, 50–75%, and 75–100%, which indicated no, low, moderate, and high heterogeneity, respectively. A fixed-effect model (the inverse variance method for MD and HR as well as



Figure 1. A PRISMA flow diagram for integrated analysis study selection.

Table 1. Comparison of baseline characteristics for selected COPD patients with increased peripheral blood eosinophils. GOLD = Global Initiative for Chronic Obstructive Lung Disease; Eos = eosinophils; Mepo = mepolizumab; Benra = benralizumab; BD = bronchodilator; ICS = inhaled corticosteroids; LABA = long-acting beta 2 agonist; LAMA = long-acting muscarinic antagonist. References: 1. Pavord ID, et al. *N Engl J Med.* 2017; 377:1613–1629. 2. Brightling CE, et al. *Lancet Respir Med.* 2014; 2:891–901. 3. Criner GJ, et al. *N Engl J Med.* 2019; 381:1023–1034.

Study	METREX1		METREO1			Brightling et	al.2	GALATHEAS	3		TERRANOVA	\3		
Inclusion criteria for eosinophils	Peripheral l the previou	blood Eos ≥ 15 s year	50/μL at screen	ing or \geq 300/µ	L during	Sputum Eos	≥3%	Peripheral blood Eos $\geq 220/\mu L$ at baseline						
	Mepo 100 mg	Placebo	Mepo 100 mg	Mepo 300 mg	Placebo	Benra 100 mg	Placebo	Benra 30 mg	Benra 100 mg	Placebo	Benra 10 mg	Benra 30 mg	Benra 100 mg	Placebo
n	233	229	223	225	226	51	50	382	379	359	377	394	386	388
Age	65 ± 8	65 ± 9	65 ± 9	65 ± 9	66 ± 9	63 ± 8	65 ± 8	66 ± 8	66 ± 8	66 ± 8	65 ± 8	66 ± 8	65 ± 8	65 ± 8
Female (%)	36	34	41	30	31	31	42	29	31	28	33	32	35	35
Current smoker (%)	27	31	25	32	28	33	42	37	34	32	29	27	28	30
Ex-smoker (%)	70	64	73	66	71	67	58	63	66	68	71	73	72	70
GOLD group D (%)	94	95	95	97	96	-	-	-	-	-	-	-	-	-
Exacerbations in the previous year	2.6 ± 1.3	$\textbf{2.5}\pm\textbf{1.2}$	$\textbf{2.5} \pm \textbf{1.2}$	$\textbf{2.7} \pm \textbf{1.4}$	2.7 ± 1.5	1.6 ± 1.0	1.6 ± 1.0	2.3 ± 1.2	$\textbf{2.3}\pm\textbf{1.2}$	$\textbf{2.4} \pm \textbf{1.4}$	$\textbf{2.3} \pm \textbf{1.0}$	$\textbf{2.2}\pm\textbf{1.0}$	$\textbf{2.3} \pm \textbf{1.0}$	2.3 ± 1.0
Post-BD % predicted FEV1	45 ± 15	43 ± 15	47 ± 15	45 ± 16	46 ± 15	44 ± 16	50 ± 18	42 ± 11	44 ± 12	43 ± 13	44 ± 12	43 ± 12	43 ± 12	43 ± 11
Geometric mean Eos (/mm ³)	260	290	300	310	310	-	-	-	-	-	-	-	-	-
Baseline mean Eos (/mm ³)	-	-	-	-	-	249 ± 193	230 ± 165	451 ± 281	459 ± 277	450 ± 283	518 ± 420	503 ± 389	504 ± 404	493 ± 360
ICS/LABA/LAMA (%)	100					50	41	72.3	69.1	67.4	57.3	56.9	61.4	59.0
ICS/LABA (%)	-					10	10	18.8	21.1	24.0	34.7	32.3	34.5	34.3
LABA/LAMA (%)	-					-		8.6	9.8	8.6	7.7	10.7	4.1	6.4
Current asthma (%)	excluded					excluded		4.5	6.9	5.0	1.6	4.3	3.1	4.1
Previous history of asthma (%)	excluded fo	r never smoke	rs with a histor	y of asthma		-		6.8	10.0	8.1	4.8	5.3	7.3	7.2

ω

Α	Moderate-to-severe exacerbation	S							
	Study	Intervention	Placebo	log(RR)	SE		RR	95%-CI	Weight
	benralizumab NCT02138916 (GALATHEA: 30 mg sc) NCT0215660 (TERRANOVA: 30 mg sc) Fixed effect model Heterogeneity: $f^2 = 0\%$, $r^2 = 0$, $p = 0.53$ Test for effect in subgroup: $z = 0.04$ ($p = 0.97$	382 394 776	359 388 747	-0.04 0.04	0.0930 0.0852		0.96 1.04 1.00	[0.80; 1.15] [0.88; 1.23] [0.89; 1.13]	25.6% 30.5% 56.0%
Approved dose	mepolizumab					_			
for severe asthma	NCT02105948 (METREX: 100 mg sc) NCT02105961 (METREO: 100 mg sc) Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $\rho = 0.86$	233 223 456	229 226 455	-0.20 -0.22	0.0955 0.1059 ·	-	0.82 0.80 0.81	[0.68; 0.99] [0.65; 0.98] [0.71; 0.93]	24.3% 19.7% 44.0%
	Test for effect in subgroup: $z = -2.95$ ($p < 0.0$)							
	Fixed effect model Heterogeneity: $l^2 = 45\%$, $\tau^2 = 0.0073$, $p = 0.14$ Test for overall effect: $z = -1.93$ ($p = 0.05$)	1232	1202			0.75 1 1	ן 0.91 ו.5	[0.83; 1.00]	100.0%
	Test for subgroup differences: χ_1^2 = 5.01, df =	1 (p = 0.03)			Favo	ors intervention Favors place	oo		
1	Study	Intervention	Placeb	o log(RR	SE		RR	95%-CI	Weight
	benralizumab NCT01227278 (Brightling 2014: 100 mg sc) NCT02138916 (GALATHEA: 100 mg sc) NCT02156560 (TERRANOVA: 100 mg sc) Fixed effect model Heterogeneity. $7^2 = 0\%$, $r^2 = 0$, $p = 0.54$ Test for effect in subgroup: $z = -1.83$ ($p = 0.07$) 4(379 386 809	0 4 9 35 6 38 5 78	2 0.03 9 -0.19 8 -0.07	0.2194 0.0943 0.0897	-	- 1.03 0.83 0.93 0.89	[0.67; 1.58] [0.69; 1.00] [0.78; 1.11] [0.79; 1.01]	6.0% 32.3% 35.7% 74.0%
High dose 🥣	mepolizumab NCT02105961 (METREO: 300 mg sc) Fixed effect model Heterogeneity: not applicable Test for effect in subgroup: z = -1,44 (p = 0.15	22 22	5 22 5 22	6 -0.15 6	0.1050	-	0.86 0.86	[0.70; 1.06] [0.70; 1.06]	26.0% 26.0%
	Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $p = 0.72$ Test for overall effect: $z = -2.31$ ($p = 0.02$) Test for subgroup differences: $\chi_1^2 = 0.09$, df = 1	103 (<i>p</i> = 0.76)	0 101	5	Fav	0.75 1 1 rors intervention Favors place	0.88 .5 bo	[0.80; 0.98]	100.0%

В

Time to first moderate to severe exacerbations

	Study	Intervention	Placebo	log(HR)	SE		HR	95%-CI	Weight
Approved dose for severe asthma	mepolizumab NCT02105948 (METREX: 100 mg sc) NCT02105961 (METREO: 100 mg sc) Fixed effect model Heterogeneity: $j^2 = 0\%, r_s^2 = 0, p = 0.60$ Test for effect in subgroup: $z = -2.93$ ($p < 0$	233 223 456	229 226 455	-0.29 (-0.20 (0.1139 — 0.1264		0.75 0.82 0.78	[0.60; 0.94] [0.64; 1.05] [0.66; 0.92]	55.2% 44.8% 100.0%
	Fixed effect model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.60$ Test for overall effect: $z = -2.93$ ($p < 0.01$) Test for subgroup differences: $\chi_0^2 = 0.00$, d	456 f = 0 (p = NA)	455		Favor	0.75 1 1.5 s intervention Favors place	0.78 	[0.66; 0.92]	100.0%
Ì	Study	Intervention	Placebo	log(HR)	SE		HR	95%-CI	Weight
High dose 🥣	mepolizumab NCT02105961 (METREO: 300 mg sc) Fixed effect model Haterogeneity: not applicable Test for effect in subgroup: $z = -2.05 (p =$ Test for subgroup differences: $\chi_0^2 = 0.00$, c	225 225 0.04) ff = 0 (p = NA)	226 226	-0.26	0.1273 -	0.75 1 1.	0.77 0.77	[0.6; 0.99] [0.6; 0.99]	100.0% 100.0%

С

Exacerbations leading to an emergency department visit or hospitalization

	Γ	Study	ntervention	Placebo	log(RR)	SE		RR	95%-CI	Weight
		benralizumab NCT02138916 (GALATHEA: 30 mg sc) NCT02158600 (TERRANOVA: 30 mg sc) Fixed effect model Heterogeneity: $\ell^2 = 0\%, \epsilon^2 = 0, p = 0.48$ Test for effect in subgroup: $z = -0.36$ ($p = 0.72$)	382 394 776	359 388 747	0.06 -0.12	0.1903 0.1603		1.06 0.89 0.96	[0.73; 1.54] [0.65; 1.22] [0.75; 1.22]	26.7% 37.6% 64.3%
Approved dose for severe asthma		mepolizumab NCT02105948 (METREX: 100 mg sc) NCT02105964 (METRED: 100 mg sc) Fixed effect model Heterogeneity: $J^2 = 75\%$, $\tau^2 = 0.1712$, $p = 0.05$ Test for effect in subgroup: $z = -0.66$ ($p = 0.51$)	233 223 456	229 226 455	0.15 -0.53	0.2091 0.2664 —		1.16 0.59 0.90	[0.77; 1.75] [0.35; 0.99] [0.65; 1.24]	22.1% 13.6% 35.7%
		Fixed effect model Heterogeneity: $l^2 = 34\%$, $\tau^2 = 0.0212$, $p = 0.21$ Test for overall effect: $z = -0.68$ ($p = 0.49$)	1232	1202			0.5 1 2	0.93	[0.77; 1.13]	100.0%
	2	Test for subgroup differences: $\chi_1^* = 0.10$, df = 1 Study	(p = 0.75) Interventio	n Placeb	o loa(RR	Favor () SE	rs intervention Favors placeb	o Rf	R 95%-C	l Weight
		harmeline meh				,	7 T			.
		Denraiiziumab NCT02138916 (GALATHEA: 100 mg sc) NCT02155660 (TERRANOVA: 100 mg sc) Fixed effect model Heterogeneity: $J^2 = 0\%$, $\tau^2 = 0$, $\rho = 0.59$ Test for effect in subgroup: $z = -3.53$ ($\rho < 0.01$)	37 38 76	9 35 6 38 5 74	9 -0.5 8 -0.4 7	4 0.2025 0 0.1702		0.50 0.6 0.6	8 [0.39; 0.86 7 [0.48; 0.94 3 [0.49; 0.81] 32.5%] 46.0%] 78.4%
High dose 🥌		mepolizumab NCT02105961 (METREO: 300 mg sc) Fixed effect model Heterogeneity: nct applicable Test for effect in subgroup: z = -0.75 (p = 0.45)	22 22	5 22 5 22	6 -0.1 6	9 0.2485		0.8 0.8	3 [0.51; 1.35 3 [0.51; 1.35] 21.6%] 21.6%
		Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $\rho = 0.54$ Test for overall effect: $z = -3.48$ ($\rho < 0.01$) Test for subgroup differences: $\chi_1^2 = 0.95$, df = 1	99 (p = 0.33)	97	3	Favo	0.5 1 2 prs intervention Favors place	0.6	7 [0.53; 0.84] 100.0%

Figure 2. Forest plot of anti-IL-5-targeting therapy effects on moderate-to-severe exacerbations (A), the time to first moderate-to-severe exacerbation (B), and exacerbations leading to an emergency department visit or hospitalization (C) in COPD patients with increased peripheral blood eosinophils. SE = standard error; RR = risk ratio; CI = confidence interval.

Α	St. George's Respiratory Question	onnaire (S	SGRQ)) score				
	Study	Interventio Mean S	on D Total	Placebo Mean SD	Total	MD	95%-CI	Weight
	benralizumab NCT02138916 (GALATHEA: 30 mg sc) NCT02155660 (TERRANOVA: 30 mg sc) Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $\rho = 0.69$ Test for effect in subgroup: $z = -1.63$ ($\rho = 0.10$	-5.025 14.67 -8.674 17.91)	7 338 0 329 667	-3.913 15.039 -6.863 16.344	317 349 666	-1.11 -1.81 -1.42	[-3.39; 1.17] [-4.40; 0.77] [-3.13; 0.29]	33.2% 25.8% 59.0%
Approved dose for severe asthma	mepolizumab NCT02105948 (METREX: 100 mg sc) NCT02105961 (METREC: 100 mg sc) Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $p = 0.32$ Test for effect in subgroup: $z = -0.91$ ($p = 0.36$	-2.800 16.53 -5.000 14.76	37 226 5 218 444	-3.000 16.092 -3.100 14.765	214 218 432	0.20 -1.90 -0.95	[-2.85; 3.25] [-4.67; 0.87] [-3.00; 1.10]	18.5% 22.4% 41.0%
	Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $p = 0.74$ Test for overall effect: $z = -1.83$ ($p = 0.07$) Test for subgroup differences: $\gamma_4^2 = 0.12$, df = 1	(p = 0.73)	1111		1098 -4 -2 0 2 Favors intervention Favors place	-1.23	[-2.54; 0.09]	100.0%
	Study	Interventio	on D Total	Placebo Mean SD	Total	MD	95%-CI	Weight
	benralizumab NCT01227278 (Brightling 2014: 100 mg sc) NCT02138916 (GALATHEA: 100 mg sc) NCT02155660 (TERRANOVA: 100 mg sc) Fixed effect model Heterogeneity: $J^2 = 0\%$, $\tau^2 = 0.0075$, $p = 0.37$ Test for effect in subgroup: $z = -1.90$ ($p = 0.06$)	-5.510 16.64 -6.723 15.72 -7.257 15.98	40 40 23 331 39 354 725	-4.430 11.710 -3.913 15.039 -6.863 16.344	42 317 349 708	-1.08 -2.81 -0.39 -1.58	[-7.34; 5.18] [-5.18; -0.44] [-2.78; 2.00] [-3.20; 0.05]	5.0% 35.0% 34.4% 74.4%
High dose 🦟	mepolizumab NCT02105961 (METREO: 300 mg sc) Fixed effect model Heterogeneity: not applicable Test for effect in subgroup: z = -0.14 (p = 0.89)	-3.300 14.79	9 219 219	-3.100 14.765	218	-0.20 -0.20	[-2.97; 2.57] [-2.97; 2.57]	25.6% 25.6%
	Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $p = 0.44$ Test for overall effect: $z = -1.71$ ($p = 0.09$) Test for subgroup differences: $\chi_1^2 = 0.71$, df = 1 (<i>p</i> = 0.40)	944		926 -6 -4 -2 0 2 4 6 Favors intervention Favors place	-1.23 bo	[-2.63; 0.18]	100.0%

В

COPD assessment test (CAT) score

	Study	Intervention Mean SD Tota	Placebo al Mean SD T	Fotal	MD 95%-CI Weight
	benralizumab NCT02138916 (GALATHEA: 30 mg sc) NCT02155660 (TERRANOVA: 30 mg sc Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $\rho = 0.78$ Test for effect in subgroup: $z = -0.47$ ($\rho = 0.6$	-1.500 6.690 33) -2.430 7.180 33 66	8 -1.220 6.530 1 -2.360 6.540 9	319	-0.28 [-1.31; 0.75] 29.3% -0.07 [-1.10; 0.96] 28.9% -0.18 [-0.90; 0.55] 58.2%
Approved dose for severe asthma	mepolizumab NCT02105948 (METREX: 100 mg sc) NCT02105961 (METREC: 100 mg sc) Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $\rho = 0.65$ Test for effect in subgroup: $z = -2.32$ ($\rho = 0.05$	-0.800 6.735 22 -1.600 6.173 21 44	4 0.000 6.843 6 -0.400 6.258 0	212 222 434	-0.80 [-2.08; 0.48] 19.0% -1.20 [-2.36; -0.04] 22.8% -1.02 [-1.88; -0.16] 41.8%
	Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $p = 0.49$ Test for overall effect: $z = -1.86$ ($p = 0.06$) Test for subgroup differences: $\chi_1^2 = 2.15$, df =	110 1 (<i>p</i> = 0.14)	9	-2 -1 0 1 2 Favors intervention Favors placebo	-0.53 [-1.08; 0.03] 100.0%
	Study	Intervention Mean SD Tot	Placebo tal Mean SD	Total	MD 95%-CI Weight
	benralizumab NCT02138916 (GALATHEA: 100 mg sc) NCT02155660 (TERRANOVA: 100 mg sc) Fixed effect model Heterogeneity: $l^2 = 66\%$, $\tau^2 = 0.4813$, $p = 0.0$ Test for effect in subgroup: $z = -1.69$ ($p = 0.0$	-2.430 6.340 33 c) -2.360 6.670 3 6 99 9)	35 -1.220 6.530 54 -2.360 6.540 89	319	-1.21 [-2.20; -0.22] 36.5% 0.00 [-0.98; 0.98] 37.3% -0.60 [-1.29; 0.10] 73.8%
High dose 🦟	mepolizumab NCT02105961 (METREO: 300 mg sc) Fixed effect model Heterogeneity: not applicable Test for effect in subgroup: z = -0.67 (p = 0.5	-0.800 6.215 2 2	19 -0.400 6.258 19	222	-0.40 [-1.56; 0.76] 26.2% -0.40 [-1.56; 0.76] 26.2%
	Fixed effect model Heterogeneity: $l^2 = 33\%$, $\tau^2 = 0.1405$, $p = 0.2$ Test for overall effect: $z = -1.80$ ($p = 0.07$) Test for subgroup differences: $\chi_1^2 = 0.08$, df =	9 2 1 (p = 0.77)	08	891 -2 -1 0 1 2 Favors intervention Favors placeb	- 0.55 [-1.14; 0.05] 100.0%

Figure 3. Forest plot of anti-IL-5-targeting therapy effects on St. George's Respiratory Questionnaire (SGRQ) score (A) and the COPD assessment test (CAT) score (B) in COPD patients with increased peripheral blood eosinophils. SD = standard deviation; MD = mean difference; CI = confidence interval.

the Mantel-Haenszel method for RR and OR) was used when heterogeneity was absent. Otherwise, a random-effect model (the Der Simonian and Laird method) was used. We did not consider publication bias because of the low number of publications included in the study.

3. Results

3.1. Systematic review of the literature

A PRISMA flow diagram to select studies for the integrated analysis of biologics that treat COPD with increased peripheral blood eosinophils is shown in Figure 1. One Phase II clinical trial was planned for omalizumab but was withdrawn due to a lack of eligible subjects. No randomized controlled trials (RCTs) of reslizumab or tralokinumab to treat COPD were reported. Lebrikizumab completed a Phase II trial in COPD, but the results were not reported. As of 1 December, 2021, two Phase III RCTs and a Phase II RCT in COPD were planned for dupilumab and tezepelumab, respectively, and patient enrollment was underway. Three RCT results for mepolizumab [(1) NCT01463644 [7], (2) NCT02105948 (METREX), (3) NCT 02105961 (METREO) [8]] and three RCT results for benralizumab in COPD [(1) NCT01227278 [9], (2) NCT02138916 (GALATHEA), (3) NCT02155660 (TERRANOVA) [10, 11]] were reported in five papers.

3.2. Basic characteristics of the included studies

To analyze COPD patients with increased peripheral blood eosinophils, all cases reported by Dasgupta, et al. [7] (COPD patients with eosinophils >3% in sputum within the past 2 years), all cases of METREO (COPD patients with peripheral blood eosinophil count \geq 150/µL at screening or \geq 300/µL in the previous year), a subpopulation of METREX (COPD with peripheral blood eosinophil counts \geq 150/µL at screening or \geq 300/µL in the previous year) [8], all cases reported by Brightling et al. [9], subpopulations of GALATHEA and TERRANOVA (COPD with peripheral blood eosinophil count \geq 220/µL) [10] were included in the integrated analysis. For analyses of serious adverse events, death, and all adverse events, the analysis included all patients with COPD because event data stratified by COPD with increased peripheral blood eosinophils were not available in GALATHEA and TERRANOVA [10, 11]. Baseline characteristics of included studies were listed in Table 1. The

study subjects were not only COPD patients with increased peripheral blood eosinophils, but also those with frequent exacerbation that primarily took inhaled corticosteroids, and about 30% of patients who were current smokers.

Finally, the clinical efficacy of anti-IL-5-targeted therapy at approved doses for severe asthma (benralizumab 30 mg, mepolizumab 100 mg) and high (benralizumab 100 mg, mepolizumab 300 mg) doses were included in the integrated analysis of COPD patients with increased peripheral blood eosinophils. In the TERRANOVA, benralizumab 10 mg was administered subcutaneously, but these subjects were not included in the integrated analysis because it was not shown to be effective, it was a lower dose than approved, and was subject to being double counted in the placebo. The pilot study [7] was not included in the final integrated analysis because mepolizumab was administered intravenously at a higher dose of 750 mg, which is not an approved route of administration and the number of subjects was extremely small.

3.3. Clinical efficacy of anti-IL-5-targeted therapy: primary outcomes

In three RCTs of benralizumab for COPD patients (n = 4,012), 2,230 patients received benralizumab, but only 1,581 were COPD patients with increased peripheral blood eosinophils [9, 10, 11]. In three RCTs of mepolizumab for COPD patients (n = 1,530), 865 patients received mepolizumab, but only 681 COPD patients with increased peripheral blood eosinophils received mepolizumab [7, 8]. At the approved dose for severe asthma, benralizumab did not reduce moderate-to-severe exacerbations, whereas mepolizumab reduced moderate-to-severe exacerbations by 19% [RR = 0.81, 95% confidence interval (CI) [0.71, 0.93], p = 0.003]. An integrated analysis of approved benralizumab and mepolizumab doses showed a trend of 9% reduction in moderate-to-severe exacerbations (RR = 0.91, 95% CI [0.83, 1.00], *p* = 0.05, level of evidence C) (Figure 2A). At high doses, neither benralizumab nor mepolizumab reduced moderate-to-severe exacerbations, however, an integrated analysis showed a 12% reduction in moderate-to-severe exacerbations (RR = 0.88, 95% CI [0.80, 0.98], p = 0.02, level of evidence B) (Figure 2A). Approved and high doses of mepolizumab increased the time to first moderate-to-severe exacerbation by 22% (HR = 0.78, 95% CI [0.66, 0.92], p = 0.003, level of evidence B) and 23% (HR = 0.77, 95% CI [0.60, 0.99], p = 0.04, level of evidence C), respectively (Figure 2B). An integrated analysis of approved benralizumab and mepolizumab doses did not show a reduction in

Pre-bronchodilator forced expiratory volume in one second (FEV1) (L)



Figure 4. Forest plot of anti-IL-5-targeting therapy effects on pre-bronchodilator forced expiratory volume in one second (FEV1) in COPD patients with increased peripheral blood eosinophils. SD = standard deviation; MD = mean difference; CI = confidence interval.

exacerbations leading to ED visits or hospitalization (level of evidence C) (Figure 2C). High doses of benralizumab reduced exacerbations leading to an ED visit or hospitalization by 37% (RR = 0.63, 95% CI [0.49, 0.81], p = 0.0004) but high doses of mepolizumab did not. An integrated analysis of high benralizumab and mepolizumab doses showed a 33% reduction in exacerbations leading to an ED visit or hospitalization (RR = 0.67, 95% CI [0.53, 0.84], *p* = 0.0005, level of evidence B) (Figure 2C).

3.4. Clinical efficacy of anti-IL-5-targeted therapy: secondary outcomes

An integrated analysis of either approved or high doses of benralizumab and mepolizumab did not improve SGRQ scores (level of evidence C) (Figure 3A). The approved dose of mepolizumab improved the CAT

Rescue inhaler use (nuffs/day)

score by one point (mean difference (MD) = -1.02, 95% CI [-1.88, -0.16], p = 0.02), which was less than the minimal clinically important difference (MCID) of two points [19]. An integrated analysis of approved or high benralizumab and mepolizumab doses showed no improvement in CAT scores (level of evidence C) (Figure 3B). Neither approved nor high benralizumab doses improved pre-bronchodilator FEV1 (level of evidence C) (Figure 4).

Approved and high benralizumab doses reduced rescue inhaler use by 0.4 puffs/day (MD = -0.40, 95% CI [-0.77, -0.03], p = 0.03, level of evidence B) and 0.49 puffs/day (MD = -0.49, 95% CI [-0.83, -0.15], p = 0.005, level of evidence B), respectively (Figure 5A). However, these differences were below the MCID. A study evaluating the MCID of rescue inhaler use in COPD patients reported that an MCID of a four-point

A

	Research minuter use (pulls, aug)				
ĺ	Study	Intervention Mean SD	Placebo Total Mean SD	Total	MD 95%-Cl Weight
Approved dose	benralizumab NCT02138916 (GALATHEA: 30 mg sc) NCT02155660 (TERRANOVA: 30 mg sc) Fixed effect model Heterogeneity: $l^2 = 0\%$, $r^2 = 0$, $\rho = 0.73$ Test for effect in subgroup: $z = -2.12$ ($\rho = 0.03$	-0.050 3.210 -0.240 3.360	321 0.290 3.030 290 0.230 3.550 611	291 314 605	-0.34 [-0.83; 0.15] 55.4% -0.47 [-1.02; 0.08] 44.6% -0.40 [-0.77; -0.03] 100.0%
	Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $p = 0.73$ Test for overall effect: $z = -2.12$ ($p = 0.03$) Test for subgroup differences: $\chi_0^2 = 0.00$, df =	0 (p = NA)	611	605 -1 -0.5 0 0.5 Favors intervention Favors pla	
	Study	Intervention Mean SD	Placebo Total Mean SD	Total	MD 95%-CI Weight
High dose —	benralizumab NCT02138916 (GALATHEA: 100 mg sc) NCT02155660 (TERRANOVA: 100 mg sc) Fixed effect model Heterogeneity: $l^2 = 0\%$, $r^2 = 0$, $p = 0.65$ Test for effect in subgroup: $z = -2.80$ ($p < 0.01$	-0.270 2.710) -0.170 3.020	322 0.290 3.030 310 0.230 3.550 632	291	-0.56 [-1.02; -0.10] 56.1% -0.40 [-0.92; 0.12] 43.9% -0.49 [-0.83; -0.15] 100.0%
	Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $p = 0.65$ Test for overall effect: $z = -2.80$ ($p < 0.01$) Test for subgroup differences: $\chi_0^2 = 0.00$, df = 0) (p = NA)	632	-1 -0.5 0 0.5 Favors intervention Favors pl	

B



Figure 5. Forest plot of anti-IL-5-targeting therapy effects on rescue inhaler use (A) and the proportion of nights awoken (B) in COPD patients with increased peripheral blood eosinophils. SD = standard deviation; MD = mean difference; CI = confidence interval.

A

		All adverse events		Disasha	
	ſ	Study	Events Total	Events Total	OR 95%-Cl Weight
		benralizumab NCT02138916 (GALATHEA: 30 mg sc) NCT02155660 (TERRANOVA: 30 mg sc) Fixed effect model Heterogeneity: $l^2 = 0\%$, $z^2 = 0$, $p = 0.40$ Test for effect in subgroup: $z = 1.20$ ($p = 0.23$)	427 554 424 563 851 1117	421 550 406 568 827 1118	1.03 [0.78; 1.36] 33.1% 1.22 [0.93; 1.59] 34.1% 1.13 [0.93; 1.36] 67.2%
	Approved dose for severe asthma	mepolizumab NCT02105961 (METREX: 100 mg sc) NCT02105961 (METREO: 100 mg sc) Fixed effect model Heterogenetic, $l^2 = 42\%$, $r^2 = 0.0349$, $p = 0.19$ Test for effect in subgroup: $z = 0.01$ ($p = 0.99$)	332 417 191 223 523 640	342 419 185 226 527 645	0.88 [0.62; 1.24] 23.8% 1.32 [0.80; 2.19] 9.0% 1.00 [0.75; 1.33] 32.8%
		Fixed effect model Heterogeneity: $l^2 = 0\%$, $\tau^2 = 0$, $p = 0.41$ Test for overall effect: $z = 1.00$ ($p = 0.32$) Test for subgroup differences: $\chi_1^2 = 0.45$, df = 1	1374 1757 (<i>p</i> = 0.50)	1354 1763 [0.1 Favors	1.08 [093; 1.27] 100.0% 5 1 2 5 intervention Favors placebo
	ſ	Study	Intervention Events Tota	Placebo	OR 95%-CI Weight
		benralizumab NCT01227278 (Brightling 2014: 100 mg sc) NCT02138916 (GALATHEA: 100 mg sc) NCT02155660 (TERRANOVA: 100 mg sc) Fixed effect model Heterogeneity, $t^2 = 22\phi_{\rm e}, t^2 = 0.0103, \rho = 0.28$ Test for effect in subgroup: $z = 1.00 (p = 0.32)$	45 51 445 552 397 562 887 1165	41 50 421 550 406 568 5 868 1168	1.65 [0.54; 5.03] 2.1% 1.27 [0.95; 1.70] 35.7% 0.96 [0.74; 1.24] 51.8% 1.10 [0.91; 1.33] 89.6%
	High dose 🛁	mepolizumab NCT02105961 (METREO: 300 mg sc) Fixed effect model Heterogeneity: not applicable Test for effect in subgroup: z = 1.53 (p = 0.13)	196 22 196 22	5 185 226 5 185 226	1.50 [0.89; 2.51] 10.4%
		Fixed effect model Heterogeneity: $I^2 = 21\%$, $\tau^2 = 0.0104$, $p = 0.29$ Test for overall effect: $z = 1.48$ ($p = 0.14$) Test for subgroup differences: $\chi_1^2 = 1.20$, df = 1	1083 1390 (<i>p</i> = 0.27)	0 1053 1394 ┌ 0.2 Favor	2 0.5 1 2 5 rs intervention Favors placebo
В	Se	rious adverse events –	Intervention	Placebo	
		Study	Events Tota	Events Total	OR 95%-CI Weight
		benralizumab NCT021358916 (GALATHEA: 30 mg sc) NCT02155660 (TERRANOVA: 30 mg sc) Fixed effect model Heterogeneity: <i>P</i> = 79%, x ² = 0.0635, <i>p</i> = 0.02 Test for effect in subgroup: z = -0.26 (<i>p</i> = 0.75	151 554 177 563 328 1117	176 550 158 568 334 1118	0.80 [0.61; 1.03] 33.7% 1.19 [0.92; 1.54] 28.3% 0.98 [0.61; 1.17] 62.0%
	Approved dose for severe asthma	mepolizumab NCT02105948 (METREX: 100 mg sc) NCT02105961 (METREO: 100 mg sc) Fixed effect model Heterogeneity: $r^2 = 0\%, r^2 = 0, p = 0.85$ Test for effect in subgroup: $z = -1.57$ ($p = 0.12$	115 417 57 223 172 640	131 419 68 226 — 199 645	0.84 [0.62; 1.13] 24.8% 0.80 [0.53; 1.21] 13.2% 0.82 [0.65; 1.05] 38.0%
		Fixed effect model Heterogeneity: $l^2 = 49\%$, $\tau^2 = 0.0222$, $p = 0.12$ Test for overall effect: $z = -1.16$ ($p = 0.25$) Test for subgroup differences: $\chi_1^2 = 1.21$, df = t^2	500 1757 (<i>p</i> = 0.27)	533 1763 Favors	0.92 [079; 1.06] 100.0% 0.75 1 1.5 s intervention Favors placebo
	ſ	Study	Intervention Events Tota	Placebo	OR 95%-CI Weight
		benralizumab NCT01227278 (Brightling 2014: 100 mg sc) NCT02138916 (GALATHEA: 100 mg sc) NCT02155660 (TERRANOVA: 100 mg sc) Fixed effect model Heterogeneity: $f^2 = 51\%$, $\tau^2 = 0.0333$, $p = 0.13$ Test for effect in subgroup: z = -1.12 ($p = 0.26$)	14 51 177 552 127 562 318 1165	9 50 176 550 158 568 343 1168	1,72 [167; 4.45] 2.2% 1,00 [178; 129] 40.2% 0,76 [158; 0.99] 40.9% 0,90 [0.75; 1.08] 83.3%
	High dose 🥌	benralizumab NCT012227276 (Brightling 2014: 100 mg sc) NCT02138916 (GALATHEA: 100 mg sc) NCT0215560 (TERRANOVA: 100 mg sc) Fixed affect model Heterogeneity: a 51%, a ² do 0.033, p = 0.13 Tren for effect in subgroup: z = -1.72 (p = 0.28) mepolizumab NCT02156961 (METREC: 300 mg sc) Fixed affect model Heterogeneity: not applicable Tents for effect in subgroup: z = -0.81 (p = 0.42)	14 51 177 55 127 56 318 116 60 225 60 225	9 50 176 550 158 568 343 1168 68 226 68 226	1,72 [C67; 4.45] 2.2% 1,00 [C78; 1.29] 40.2% 0,90 [0.75; 1.08] 83.3% 0,90 [0.75; 1.08] 83.3% 0,84 [C56; 127] 16.7% 0.84 [0.56; 1.27] 16.7%
	High dose —	benralizumab NCT01222728 (Briphtling 2014: 100 mg sc) NCT02138916 (GALATHEA: 100 mg sc) NCT0215560 (TERRANOV4: 100 mg sc) Fixed effect model Hetergonely: $r^2 = 51\%$, $r^2 = 0.033$, $p = 0.13$ Test for effect model NCT02109661 (METREO: 300 mg sc) Fixed effect model method effect model Test for effect model Hetergonenity: $r^2 = 25\%$, $r^2 = 0.0128$, $p = 0.25$ Test for versile effect $r = 0.326$ ($p = 0.42$) Test for scale effect $r = 0.426$ ($p = 0.12$) Test for scale effect $r = 0.426$ ($p = 0.12$)	14 51 177 55; 127 56; 318 116; 60 22; 60 22; 378 139((p = 0.78)	9 50 176 550 158 568 343 1168 68 226 68 226 0 411 1394 Favor	1,72 [C67; 4.45] 2.2% 1,00 [C78; 1.29] 40.2% 0,90 [0.75; 1.08] 83.3% 0,84 [C56; 1.27] 16.7% 0.84 [C56; 1.27] 16.7% 0.84 [C56; 1.27] 16.7% 0.84 [C56; 1.27] 16.7% 0.84 [C56; 1.27] 10.0% 0,5 1 2 intervention Favors placebo
	High dose —	benralizumab NCT01222726 (Briphtling 2014: 100 mg sc) NCT02133916 (GALATHEA: 100 mg sc) NCT02155060 (FERRANOVA: 100 mg sc) Fixed offset model Heterogeneity: $a \pm 13, a = 0.333, p = 0.13$ Test for effect m subgroup: $z = -1.12$ ($p = 0.26$) NCT02150606 (METREC: 300 mg sc) Fixed effset model Heterogeneity: not applicable Test for effect model Heterogeneity: $f^2 = 283, x^2 = 0.0128, p = 0.25$ Test for even effect: $a = 0.38, x^2 = 0.0128, p = 0.25$ Test for even effect: $a = 0.38, x^2 = 0.0128, p = 0.25$ Test for sven effect: $a = 0.38, x^2 = 0.0128, p = 0.25$ Test for sven effect: $a = 0.38, x^2 = 0.0128, p = 0.25$	14 55 177 55 127 56 318 116 60 225 378 1390 (p = 0.78)	9 50 176 550 158 558 343 1168 68 226 68 226 411 1394 Favor	1,72 [C67; 4.45] 2.2% 1,00 [C78; 1.29] 40.2% 0,90 [0.75; 1.08] 83.3% 0,84 [C56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.89 [0.76; 1.05] 100.0% 0,5 1 2 s intervention Favors placebo
С	High dose –	benatizumab NCT01222768 (Biphthing 2014: 100 mg sc) NCT02133916 (GALATHEA: 100 mg sc) NCT02153060 (FERRANOV: 100 mg sc) Fixed offset model Heterogeneity: $a \le 1, a \le 2, a \le 3, a $	14 55 177 555 318 1165 60 225 60 223 378 1390 (<i>p</i> = 0.78)	9 50 176 550 158 558 343 1168 68 226 68 226 0 411 1394 Favor	1,72 [C67; 4.45] 2.2% 1,00 [C78; 1.29] 40.2% 0,90 [0.75; 1.08] 83.3% 0,84 [C56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.89 [0.76; 1.05] 100.0% 0,5 1 2 s intervention Favors placebo
С	High dose —	benalizumab NCT0222726 (Biphilling 2014: 100 mg sc) NCT022359(6 (Biphilling 2014: 100 mg sc) NCT0215596 (Biphilling 2014: 100 mg sc) Fixed offset model Heterogeneity: $z = 1, 12 \ (p = 0.28)$ mapolizumab NCT0215069((METREC: 300 mg sc) Fixed offset model Heterogeneity: nct applicable Test for offset model Heterogeneity: $r^2 = 28, r^2 = 0.018, p = 0.25$ Test for overall effect: $z = -1.36 \ (p = 1.8)$ Test for scale left: $z = -1.80$ Test for scale left: $z = -1.$	14 55 177 555 318 1165 60 222 60 223 378 1390 (<i>p</i> = 0.78)	9 50 176 550 158 568 343 1168 68 226 68 226 68 226 9 411 1394 Favore Placebo Events Total	1,72 (C67; 4.45) 2,2% 1,00 (Z78; 1.29) 40.2% 0,90 (Z75; 1.08) 83.3% 0,90 (Z75; 1.08) 83.3% 0,90 (Z75; 1.08) 83.3% 0,84 (C56; 1.27) 16.7% 0,84 (C56; 1.27) 16.7% 0,84 (C56; 1.27) 16.7% 0,89 (D76; 1.05) 100.0% 0,95%-CI Weight
С	High dose –	benalizumab NCT0222726 (Briphiling 2014: 100 mg sc) NCT02138916 (GALATHEA: 100 mg sc) NCT02135960 (TERRANOVA: 100 mg sc) Fixed effect model Heterogeneity: 7 = 51%, 7 = 0.0333, μ = 0.13 Train for effect model Heterogeneity: not applicable Train for effect model Heterogeneity: not applicable Train for effect model Heterogeneity: 7 = 28%, 7 = 0.0128, μ = 0.25 Train for effect model Heterogeneity: 7 = 28%, 7 = 0.0128, μ = 0.25 Train for effect model Heterogeneity: 7 = 28%, 7 = 0.0128, μ = 0.25 Train for effect model Heterogeneity: 7 = 28%, 7 = 0.08, d = 1 Decth Study benalizumab NCT02138016 (GALATHEA: 30 mg sc) NCT02138016 (GHERANOVA: 30 mg sc) NCT0215600 (TERANOVA: 30 mg sc) NCT0215600 (TERANOVA: 30 mg sc) NCT0215600 (TERANOVA: 30 mg sc) NCT0215600 (TERANOVA: 30 mg sc) NCT02138016 (TERANOVA: 30 mg sc) NCT0215	14 51 177 55 127 56 318 116 60 222 60 225 378 139(<i>ip</i> = 0.78) Intervention Events Total 15 554 21 555 36 1117	9 50 176 550 158 568 343 1168 68 226 68 226 68 226 0 411 1394 Favor Placebo Events Total 13 550 19 568 32 1118	1,72 [C67; 4.45] 2.2% 1,00 [Z78; 1.29] 40.2% 0,76 [C58] 0.99 40.9% 0,90 [0.75; 1.08] 83.3% 0,84 [C56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 1.5 [0.54; 2.44] 22.7% 1.15 [0.54; 2.44] 22.7% 1.13 [0.70; 1.84] 55.2%
С	High dose -	benalizumab NCT0222726 (Biphilling 2014: 100 mg sc) NCT0223596 (Biphilling 2014: 100 mg sc) NCT0213596 (CHERNAUOX: 100 mg sc) Fixed effect model Heterogenety: $f^2 = 51\%$, $f^2 = 0.333$, $p = 0.13$ Train for effect model Heterogenety: $r = 1.5\%$, $r^2 = 0.033$, $p = 0.26$ Fixed effect model Heterogenety: $f^2 = 25\%$, $f^2 = 0.0128$, $p = 0.26$ Train for effect model Heterogenety: $f^2 = 25\%$, $f^2 = 0.0128$, $p = 0.26$ Train for effect model Heterogenety: $f^2 = 25\%$, $f^2 = 0.0128$, $p = 0.26$ Train for effect model Heterogenety: $f^2 = 25\%$, $f^2 = 0.0128$, $p = 0.26$ Train for effect model Heterogenety: $f^2 = 25\%$, $f^2 = 0.0128$, $p = 0.26$ Train for effect model Heterogenety: $f^2 = 25\%$, $f^2 = 0.0128$, $p = 0.26$ Train for effect model Heterogenety: $f^2 = 0.0128$, $p = 0.26$ Train for effect model Heterogenety: $f^2 = 0.000$, $d = 1$ Train for effect in subgroup: $z = 0.50$ ($p = 0.26$) mepolizumab NCT022156560 (METREX: 100 mg sc) NCT022156560 (METREX: 100 mg sc) NCT02215670 (METREX: 100 mg sc) NCT021570 (METRE	14 51 177 555 127 566 318 1165 60 222 378 1390 (p = 0.78) Intervention Events Total 15 555 21 565 35 1117 16 417 4 223 20 646	9 50 176 550 159 560 343 1168 68 226 68 226 9 411 1394 Favon Placebo Events Total 13 550 19 568 32 1116 17 419 9 226 	1,72 [C67; 4.45] 2.2% 1,00 [C78; 1.29] 40.2% 0,76 [C58] 0.99] 40.9% 0,90 [0.75; 1.08] 83.3% 0.84 [C56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.89 [0.76; 1.05] 100.0% 0,5 1 2 0,89 [0.76; 1.05] 100.0% 1,15 [0.54; 2.44] 22.7% 1,12 [0.60; 1.27] 13.25% 1,13 [0.70; 1.89] 55.2% 0,94 [0.47; 1.89] 29.1% 0.44 [0.13; 1.45] 15.7% 0,77 [0.42; 1.39] 44.8%
С	High dose -	benalizumab NCT0222726 (Biphiling 2014: 100 mg sc) NCT0221580 (GALATHEA: 100 mg sc) NCT021580 (GHZNHTCA: 100 mg sc) Fixed effect model Henrogeneity: $r = 51\%, r^2 = 0.333, \mu = 0.13$ Trut for effect model Henrogeneity: $r = 51\%, r^2 = 0.033$, $\mu = 0.13$ I'tent for effect model Henrogeneity: $r = 2012$ Fixed effect model NCT0215806 (TERRANOVA: 30 mg sc) Fixed effect model Henrogeneity: $r = 0.50$ Fixed effect model Henrogeneity: $r = 0.50$ Fixed effect model NCT0215806 (TERRANOVA: 30 mg sc) Fixed effect model NCT0215806 (HETREX: 100 mg sc) Fixed effect model NCT0215806 (HETREX: 100 mg sc) Fixed effect model Henrogeneity: $r = 0.57$ ($\mu = 0.38$ Test for overall effect: $r = 0.257$ ($\mu = 0.38$ Test for overall effect: $r = 0.257$ ($\mu = 0.38$ Test for overall effect: $r = 0.257$ ($\mu = 0.38$ Test for overall effect: $r = 0.257$ ($\mu = 0.38$ Test for overall effect: $r = 0.27$ ($\mu = 0.38$ Test for overall effect: $r = 0.27$ ($\mu = 0.38$ Test for overall effect: $r = 0.17$ ($\mu = 0.38$) Test for overall effect: $r = 0.17$ ($\mu = 0.38$) Test for overall effect: $r = 0.17$ ($\mu = 0.37$)	14 51 177 55; 127 56; 318 1165 60 222 60 223 378 139((p = 0.78) Intervention Events Total 15 554 36 1117 16 417 4 222 20 646 56 1757 (p = 0.32)	9 50 1776 550 1755 568 343 1168 68 226 68 226 68 226 9 411 1394 Favor Placebo Events Total 13 550 19 568 32 1118 17 419 9 265 58 1763 50 58 1763 50 59 176 50 50 50 50 50 50 50 50 50 50	1,72 [C67; 4.45] 2.2% 1,00 [C78; 1.29] 40.2% 0,76 [C58; 0.99] 40.9% 0,90 [0.75; 1.08] 83.3% 0,84 [C56; 1.27] 16.7% 0.84 [0.56; 1.27] 15.7% 0.84 [0.56; 1.27] 15.7% 0.84 [0.56; 1.27] 15.7% 0.97 [0.76; 1.05] 100.0% 0,5 1 2 0,602 [11] 2.2% 1.13 [0.70; 1.84] 55.2% 0.94 [0.47; 1.99] 29.1% 0.77 [0.42; 1.39] 44.8% 0.97 [067; 1.41] 100.0% 0.77 [0.42; 1.39] 44.8% 0.97 [067; 1.41] 100.0%
С	High dose	benalizumab NCT0222726 (Biphiling 2014: 100 mg sc) NCT0221580 (GALATHEA: 100 mg sc) NCT021580 (GHZMATUCA: 100 mg sc) Fixed effect model Hearogeneity: $a 51\%, a^2 + 0.333, \mu = 0.13$ Trut for effect model Hearogeneity: $a 51\%, a^2 + 0.333$ Trut for effect model Hearogeneity: $a 51\%, a^2 + 0.31$ ($\mu = 0.42$) Fixed effect model Hearogeneity: $a 2\%, a^2 + 0.31$ ($\mu = 0.42$) Fixed effect model Hearogeneity: $a 2\%, a^2 + 0.31$ ($\mu = 0.42$) Fixed effect model Hearogeneity: $a 2\%, a^2 + 0.31$ ($\mu = 0.42$) Fixed effect model Hearogeneity: $a 2\%, a^2 + 0.0128, \mu = 0.25$ Trut for subgroup differences: $\chi_1^2 = 0.018, \mu = 0.25$ Study benralizumab NCT02138016 (GALATHEA: 30 mg sc) NCT02138016 (GHZRANOX: 30 mg sc) Fixed effect model Hearogeneity: $a 0\%, a^2 - 0, \mu = 0.96$ Test for effect in subgroup: $x = 0.50$ ($\mu = 0.92$) Test for effect in subgroup: $x = 0.50$ ($\mu = 0.32$) Test for effect in subgroup: $x = 0.50$ ($\mu = 0.32$) Test for overall effect: $a 0, \mu = 0.57$ Test for overall effect: $a 0, \eta = 0.57$	14 51 177 55; 127 56; 318 1165 60 222 60 223 378 139((p = 0.78) Intervention Events Total 15 554 36 1117 16 417 4 223 56 1757 (p = 0.32) Intervention Events Total	9 50 177 650 175 650 158 650 343 1168 68 226 68 226 9 411 1394 Favor Placebo Events Total 13 550 19 568 32 1118 17 419 9 226 58 1763 (Favor Placebo Events Total	1,72 [C67; 4.45] 2.2% 1,00 [C78; 1.29] 40.2% 0,76 [C58; 0.9] 40.9% 0,90 [0.75; 1.08] 83.3% 0,84 [C56; 1.27] 16.7% 0.84 [0.56; 1.27] 15.7% 0.94 [0.76; 1.05] 100.0% 1.13 [0.70; 1.84] 55.2% 0.94 [0.47; 1.19] 29.1% 0.44 [0.13; 1.45] 15.2% 0.97 [0.67; 1.14] 100.0% 0.97 [0.67; 1.14] 100.0% 0.97 [0.67; 1.14] 100.0% 0.97 [0.67; 1.14] 100.0% 0.97 [0.67; 1.14] 100.0%
С	High dose -	benralizumab NCT0222726 (Biphiling 2014: 100 mg sc) NCT0223586 (Biphiling 2014: 100 mg sc) NCT0213586 (CHERNAUOX: 100 mg sc) Fixed effect model Heterogeneity: 7 = 51%, 7 = 0.033, μ = 0.13 Trut for effect model Heterogeneity: not applicable Trat for effect model Heterogeneity: 7 = 28%, 7 = 0.0128, μ = 0.25 Fixed effect model Heterogeneity: 7 = 28%, 7 = 0.0128, μ = 0.25 Trat for effect model Heterogeneity: 7 = 28%, 7 = 0.0128, μ = 0.25 Trat for effect model Heterogeneity: 7 = 28%, 7 = 0.0128, μ = 0.25 Trat for effect model Heterogeneity: 7 = 0.00, 7 = 0.00, ff = 1 Test for subgroup differences: $\chi_1^2 = 0.08$, df = 1 Dearth Study benralizumab NCT02159546 (METREX: 100 mg sc) NCT02159546 (METREX: 100 mg sc) NCT0215954 (METREX: 100 mg sc) NCT02159546 (METREX: 100 mg sc) NCT0215954 (METREX: 100 mg sc	14 51 177 55 127 56 318 1165 60 222 60 223 378 139((p = 0.78) Interventior Events Total 15 554 21 566 36 1117 16 417 4 223 20 646 (p = 0.32) Intervention Events Total	9 50 176 650 158 668 158 668 266 226 68 226 68 226 68 226 9 411 1394 Favor Placebo Events Total 13 550 19 568 32 1118 17 419 9 226 - 58 1763 65 1763 0 Favor Placebo Events Total	1,72 [C67; 4.45] 2.2% 1,00 [C78; 1.29] 40.2% 0,76 [C58; 0.99] 40.9% 0,90 [0.75; 1.08] 83.3% 0,84 [C56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.94 [0.47; 1.89] 29.1% 0.44 [0.13; 1.45] 15.2% 0.94 [0.47; 1.89] 29.1% 0.44 [0.13; 1.45] 15.7% 0.77 [6.42; 1.39] 4.8% 0.97 [0.67; 1.41] 100.0% 0.77 [6.42; 1.39] 4.8% 0.77 [6.42; 1.39] 4.8% 0.77 [6.42; 1.39] 4.8% 0.77 [6.42; 1.39] 4.8% 0.77 [6.42; 1.39] 4.9% 0.77 [6.42; 1.39] 4.9%
С	High dose -	benalizumab NCT0222726 (Biphiling 2014: 100 mg sc) NCT0221580 (GALATHEA: 100 mg sc) NCT021580 (GHZMATUCA: 100 mg sc) Fixed effect model Henrogeneity: $ra 51\%, r^2 + 0.033, \mu = 0.13$ Trut for effect model Henrogeneity: $ra 1\%, r^2 + 0.033, \mu = 0.13$ Trut for effect model Henrogeneity: $ra 1\%, r^2 + 0.033, \mu = 0.13$ Trut for effect model Henrogeneity: $ra 1\%, r^2 + 0.033, \mu = 0.25$ Fixed effect model Henrogeneity: $ra 1\%, r^2 + 0.033, \mu = 0.25$ Trut for effect model Henrogeneity: $ra 1\%, r^2 + 20\%, r^2 = 0.0128, \mu = 0.25$ Trut for effect model Henrogeneity: $ra 1\%, r^2 + 20\%, r^2 = 0.0128, \mu = 0.25$ Trut for subgroup differences: $\chi_1^2 = 0.08, df = 1$ Dearth Dearth Dearth Dearth Henrogeneity: $ra 0\%, r^2 = 0, \mu = 0.36$ Trut for effect model Henrogeneity: $ra 0\%, r^2 = 0, \mu = 0.36$ Trut for effect model Henrogeneity: $ra 0\%, r^2 = 0, \mu = 0.36$ Trut for effect model Henrogeneity: $r^2 + 0\%, r^2 = 0, \mu = 0.36$ Trut for effect model Henrogeneity: $r^2 + 0\%, r^2 = 0, \mu = 0.36$ Trut for versil effect: $ra 0.17, \mu = 0.38$ Trut for effect model Henrogeneity: $r^2 + 0\%, r^2 = 0, \mu = 0.36$ Trut for oversil effect: $ra 0.17, \mu = 0.38$ Trut for oversil effect: $ra 0.17, \mu = 0.38$ Trut for oversil effect: $ra 0.17, \mu = 0.37$ Trut for ungoing differences: $\chi_1^2 = 0.9, df = 1$ Study Dearth NCT0227556 (BipHilling 2014: 100 mg sc) NCT0227556 (BipHilling 2014: 100 mg sc) NCT0227580 (CHERANUCA: 00 mg sc) NCT027580 (CHERANUCA:	14 51 177 55; 127 56; 318 1165 60 222 60 223 378 139((p = 0.78) Intervention Events Total 15 554 21 566 36 1117 16 417 4 223 56 1757 ($p = 0.32$) Intervention Events Total 2 55 17 556 31 1165 ($p = 0.32$)	9 50 176 650 158 668 343 1168 68 226 68 226 68 226 9 411 1394 Favor Placebo Events Total 13 550 19 568 32 1118 17 419 9 226 58 1763 645 7 10 50 13 550 19 568 32 1168	172 [C67; 4.45] 2.2% 1.00 [C78; 1.29] 40.2% 0.76 [C58; 0.99] 40.9% 0.90 [0.75; 1.08] 83.3% 0.84 [C56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.95 [0.56; 1.27] 16.7% 0.97 [0.56; 1.13] 100.0% 0.97 [0.57; 1.49] 29.1% 0.97 [0.57; 1.49] 29.1% 0.97 [0.57; 1.49] 12% 0.92 [042; 1.39] 44.8% 0.97 [057; 1.60] 78.5%
С	High dose -	benralizumab NCT0222756 (Birphiling 2014: 100 mg sc) NCT0221566 (Birphiling 2014: 100 mg sc) NCT0215666 (DTERRANOVA: 100 mg sc) Fixed affect model Henrogeneity: $r^2 = 51\%, r^2 = 0.333, \mu = 0.13$ Trut for effect model Henrogeneity: $r^2 = 51\%, r^2 = 0.033, \mu = 0.13$ Trut for effect model Henrogeneity: $r^2 = 20\%, r^2 = 0.02$ Fixed effect model Henrogeneity: $r^2 = 20\%, r^2 = 0.02$ Test for effect model Henrogeneity: $r^2 = 20\%, r^2 = 0.02$ Test for effect model Henrogeneity: $r^2 = 20\%, r^2 = 0.02$ Test for overall effect: $z = -1.35 (\mu = 0.42)$ Test for overall effect: $z = -1.35 (\mu = 0.42)$ Test for overall effect: $z = -1.35 (\mu = 0.42)$ Test for overall effect: $z = -1.35 (\mu = 0.5)$ Henrogeneity: $r^2 = 20\%, r^2 = 0.00$ Test for overall effect: $z = -0.50 (\mu = 0.62)$ Fixed effect model Henrogeneity: $r^2 = 0.0\%, r^2 = 0.00$ Test for overall effect: $z = -0.50 (\mu = 0.62)$ Test for overall effect: $z = -0.50 (\mu = 0.62)$ Test for overall effect: $z = -0.50 (\mu = 0.62)$ Test for order in subgroup: $z = 0.50 (\mu = 0.22)$ Fixed effect model Henrogeneity: $r^2 = 0\%, r^2 = 0.024, \mu = 0.25$ Test for overall effect: $z = -0.71 (\mu = 0.35)$ Test for overall effect: $z = -0.71 (\mu = 0.35)$ Test for overall effect: $z = -0.71 (\mu = 0.35)$ Test for overall effect: $z = -0.71 (\mu = 0.55)$ Test for overall effect: $z = -0.71 (\mu = 0.55)$ Test for under (DEFRANOVA: 100 mg sc) NCT021538016 (CERRANOVA: 100 mg sc) NCT021538016 (CERRANOVA: 100 mg sc) NCT021538016 (CERRANOVA: 100 mg sc) Fixed effect model Henrogeneity: $r^2 = 0\%, r^2 = 0.05$ Test for under the subgroup: $z = -0.51 (\mu = 0.55)$ Test for under the model $z = 0.50$ Test for defect model Henrogeneity: $r^2 = 0\%, r^2 = 0.26 (\mu = 0.51)$ Test for under the model $z = 0.26 (\mu = 0.51)$ Test for under the model $z = 0.26 (\mu = 0.51)$ Test for under the model $z = 0.26 (\mu = 0.51)$ Test for under the model $z = 0.26 (\mu = 0.51)$	14 51 177 553 127 566 318 1165 60 222 378 1390 ($p = 0.78$) 1 Intervention 15 Events Total 15 554 20 640 21 566 36 1117 16 417 20 640 9 56 756 1757 16 421 56 1757 16 421 20 640 9 56 1757 115 16 421 9 56 117 16 12 552 12 552 31 1165 8 225 8 225	9 50 176 650 158 668 343 1168 68 226 68 226 9 411 1394 Favor Placebo Events Total 13 550 19 568 32 1178 65 1763 0 50 13 550 Placebo Events Total 0 50 13 550 9 226 9 226 9 226	172 [C67; 4.45] 2.2% 1.00 [C78; 1.29] 40.2% 0.76 [C58; 0.99] 40.9% 0.90 [0.75; 1.08] 83.3% 0.84 [C56; 1.27] 16.7% 0.84 [0.56; 1.27] 16.7% 0.95 [0.60; 2.11] 2.7% 1.13 [0.70; 1.84] 55.2% 0.94 [0.47; 1.89] 28.1% 0.97 [0.67; 1.41] 100.0% 0.77 [0.42; 1.39] 44.8% 0.97 [0.67; 1.41] 100.0% 0.97 [0.57; 1.61] 15.2% 0.97 [0.57; 1.61] 78.5% 0.98 [0.34; 2.35] 21.5% 0.89 [0.34; 2.35] 21.5%
С	High dose -	benralizumab NCT0222756 (Birphilling 2014: 100 mg sc) NCT0221556 (Birphilling 2014: 100 mg sc) Fixed affect model Henrogeneity: $r^2 = 51\%, r^2 = 0.333, \mu = 0.13$ Trut for effect model Henrogeneity: $r^2 = 51\%, r^2 = 0.333, \mu = 0.13$ Trut for effect model Henrogeneity: $r^2 = 51\%, r^2 = 0.033, \mu = 0.13$ Trut for effect model Henrogeneity: $r^2 = 20\%, r^2 = 0.0128, \mu = 0.25$ Fixed effect model Henrogeneity: $r^2 = 20\%, r^2 = 0.0128, \mu = 0.25$ Trut for effect model Henrogeneity: $r^2 = 20\%, r^2 = 0.0128, \mu = 0.25$ Trut for effect model Henrogeneity: $r^2 = 20\%, r^2 = 0.0128, \mu = 0.25$ Trut for overall effect: $z = -1.35 (\mu = 0.42)$ Trut for overall effect: $z = -1.35 (\mu = 0.5)$ Trut for a bug coup differences: $\chi^2_{\pm} = 0.08, df = 1$ Dearth Study benralizumab NCT02139516 (CH2NTHEA: 30 mg sc) NCT02150506 (TERPANOVA: 30 mg sc) Fixed effect model Henrogeneity: $r^2 = 0.50 (\mu = 0.26)$ Trut for effect in subgroup: $z = 0.50 (\mu = 0.25)$ Trut for overall effect: $r = 0.37 (\mu = 0.38)$ Fixed effect model Henrogeneity: $r^2 = 05\%, r^2 = 0.09, df = 1$ Study benralizumab NCT02215961 (GH2NTHEA: 100 mg sc) Fixed effect model Henrogeneity: $r^2 = 05\%, r^2 = 0.05 (\mu = 1.38)$ Trut for overall effect: $r = 0.37 (\mu = 0.38)$ Trut for overall effect: $r = 0.70 (\mu = 0.35)$ Trut for overall effect: $r = 0.70 (\mu = 0.35)$ Trut for overall effect: $r = 0.71 (\mu = 0.37)$ NCT02159616 (CH2NTHEA: 100 mg sc) Fixed effect model Henrogeneity: $r^2 = 0.5\%, r^2 = 0.9, gf = 1$ Study benralizumab NCT02125661 (METREC: 0.00 mg sc) Fixed effect model Henrogeneity: $r = 0.5\%, r^2 = 0.26$ Trut for effect model Henrogeneity: $r = 0.5\%, r^2 = 0.26$ Trut for effect model Henrogeneity: $r = 0.5\%, r^2 = 0.26$ Trut for effect model Henrogeneity: $r = 0.5\%, r^2 = 0.26$ Trut for effect model Henrogeneity: $r = 0.5\%, r^2 = 0.26$ Trut for effect model Henrogeneity: $r = 0.26$ ($p = 0.56$ Trut for effect model Henrogeneity: $r = 0.5\%, r^2 = 0.26$ ($p = 0.56$ Trut for effect model Henrogeneity: $r = 0.5\%,$	14 51 177 553 127 566 318 1165 60 222 378 1390 ip = 0.78) Intervention Events Total 15 554 21 566 36 1117 16 427 20 640 20 56 756 1757 Intervention Events 20 640 21 565 116 421 20 640 21 556 11757 552 31 1165 8 225 31 1165 8 225 39 1390	9 50 176 650 158 668 343 1168 68 226 68 226 9 411 1394 Favor Placebo Events Total 13 550 19 568 32 1118 17 419 9 226 58 1763 0 50 13 550 19 568 32 1168 9 226 9 20 9 20	17.2 [C67; 4.45] 2.2% 1.00 [C78; 1.29] 40.2% 0.75 [C58; 0.99] 40.9% 0.90 [C75; 1.08] 83.3% 0.84 [C56; 1.27] 16.7% 0.84 [C56; 1.27] 16.7% 0.84 [D56; 1.27] 16.7% 0.85 [D60; 2.11] 2.5% 0.84 [D56; 1.27] 16.7% 0.95 [D67; 1.41] 100.0% 0.25 1.2 5.2% 0.37 [D67; 1.41] 100.0% 0.20 0.5 1.2

Figure 6. Forest plot of anti-IL-5-targeting therapy effects on all adverse events (A), serious adverse events (B), and death (C) in patients with COPD. OR = odds ratio; CI = confidence interval.

improvement in the SGRQ score corresponded with a decrease of 0.6 puffs/day and an MCID of a 100-mL improvement in FEV1 was equivalent to a decrease of 1.3 puffs/day [20]. The approved dose of benralizumab reduced the proportion of nights awoken by 6% (MD = -0.06, 95% CI [-0.09, -0.02], p = 0.002, level of evidence B). There was a trend for high-dose benralizumab to reduce the proportion of nights awoken (MD = -0.03, 95% CI [-0.07, 0.00], p = 0.06, level of evidence C) (Figure 5B).

3.5. Clinical safety of anti-IL-5-targeted therapy

In both approved and high doses of benralizumab and mepolizumab, the incidence of all adverse events, serious adverse events, and death was comparable to placebo in patients with COPD (level of evidence C for serious adverse events, level of evidence B for all adverse events and death) (Figure 6A–C).

4. Discussion

In the present systematic review and integrated analysis, we showed statistically significant but limited benralizumab and mepolizumab efficacy at reducing moderate-to-severe exacerbations in COPD patients with increased peripheral blood eosinophils.

Approved doses of benralizumab and mepolizumab tended to reduce moderate-to-severe exacerbations by 9% but did not reduce exacerbations requiring ED visits or hospitalization or improve SGRQ or CAT scores. High doses of benralizumab and mepolizumab reduced moderateto-severe exacerbations by 12% and exacerbations leading to an ED visit or hospitalization by 33% but did not improve SGRQ or CAT scores. These data clearly demonstrate that high doses are required for anti-IL-5targeting therapy to alleviate moderate-to-severe exacerbations in COPD patients with increased peripheral blood eosinophils. When discussing clinical efficacy, it should be noted that study subjects were not only COPD patients with increased peripheral blood eosinophils, but also those with frequent exacerbation mostly taking inhaled corticosteroids and about 30% of patients were current smokers (Table 1).

Five meta-analyses for biologics in patients with COPD were published to-date. Rogliani et al. conducted a meta-analysis of biologics with differing mechanisms of action, including anti-IL-5, anti-IL-5 receptor α , ant-IL-1 β , anti-IL-1 receptor 1, anti-IL-8, and anti-tumor necrosis factor- α mAbs [12]. Unfortunately, their analysis double counted placebos in the three-group comparison of the METREO trial for mepolizumab. Lan, et al. resolved this double-counting problem by comparing the placebo with an integration of approved and high doses. However, their analysis included all COPD patients, making the effect of benralizumab and mepolizumab on COPD with increased peripheral blood eosinophils less detectable [13]. Donovan et al. conducted a dose-specific analysis of mepolizumab and benralizumab. However, there is no integrated analysis of both mepolizumab and benralizumab and there are inconsistencies with the detailed data reported on ClinicalTrial.gov, which raises questions about the accuracy of the analyses [14]. Pavord et al. reported a pre-specified meta-analysis of mepolizumab in COPD patients with increased peripheral blood eosinophils in the METREX and METREO studies and showed that the approved dose of mepolizumab reduced moderate-to-severe exacerbation by 18%, but the analysis did not consider benralizumab [15]. Zhang, et al. reported an integrated analysis of mepolizumab and benralizumab in eosinophilic COPD, which also double counted placebo in the three-group comparison in the METREO trial for mepolizumab [16]. Some previous reports considered the study subjects to have eosinophilic COPD [8, 16], but this tentative name is confused with COPD with eosinophilic airway inflammation or ACO.

The major differences between previous meta-analyses and the present study are described below. First, we conducted an integrated analysis of approved doses, those approved for severe asthma, and high doses in COPD patients with increased peripheral blood eosinophils. High doses of benralizumab and mepolizumab did not prevent the primary endpoint of moderate-to-severe exacerbations, in their respective clinical

trials, but when the two drugs were integrated for the analysis, moderateto-severe exacerbations decreased by 12%. Second, the data for benralizumab, which was not included in the original paper, was included as a secondary endpoint in the integrated analysis for exacerbations leading to an ED visit or hospitalization. By combining the detailed data reported in the CrinicalTrials.gov, the high-dose benralizumab or mepolizumab group had a 33% reduction in exacerbations leading to an ED visit or hospitalization. Third, previous meta-analyses concluded that anti-IL-5targeted therapy significantly reduced moderate-to-severe exacerbations in COPD, but our integrated analysis of two doses demonstrated that the doses approved for severe asthma were not sufficient. In our analysis, high doses, at a minimum, were required to reduce moderate-tosevere exacerbations in COPD patients with increased peripheral blood eosinophils. Finally, drug costs for these biologics are extremely expensive. Approved doses of 100 mg mepolizumab costs about \$1,550 every 4 weeks, and 30 mg benralizumab costs about \$3,100 three times a month and \$1,550 every 8 weeks. Therefore, the clinical benefits of biologics do not appear to be worth their cost for COPD patients with increased peripheral blood eosinophils.

There are several limitations to our study. First, multiple cutoff values for peripheral blood eosinophils were used to define COPD patients with increased peripheral blood eosinophils, as mentioned in the results. Second, we did not evaluate publication bias with a funnel plot analysis because of the few studies used for the integrated analysis.

5. Conclusions

The anti-IL-5-targeting biologics benralizumab and mepolizumab have limited efficacy in reducing moderate-to-severe exacerbations in COPD patients with increased peripheral blood eosinophils. Given their high costs, we do not recommend prescribing benralizumab or mepolizumab for COPD patients with increased peripheral blood eosinophils that do not have asthma complications.

Declarations

Author contribution statement

Hiroshi Ohnishi: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.

Masamitsu Eitoku: Analyzed and interpreted the data; Wrote the paper.

Akihito Yokoyama: Conceived and designed the experiments; Wrote the paper.

Declaration of interest's statement

The authors declare the following conflict of interests: Hiroshi Ohnishi and Akihito Yokoyama receive lecture fees from pharmaceutical companies including AstraZeneca K.K., Japan, GlaxsoSmithKline plc, Japan, Novartis Pharma, Japan, and Sanofi K.K., Japan, which supply biologics for severe asthma.

Data availability statement

Data included in article/supp. material/referenced in article.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Additional information

No additional information is available for this paper.

H. Ohnishi et al.

References

- Global Initiative for chronic obstructive Lung Disease (GOLD), Global Strategy for Diagnosis, Management and Prevention of chronic obstructive pulmonary disease 2022 Report, Available from, https://goldcopd.org-gold-reports-2/, 2022. Accessed April 8, 2022.
- [2] W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, G.D. Cioppa, A. van As, N. Gupta, Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma, J. Allergy Clin. Immunol. 108 (2) (2001) 184–190.
- [3] M. Castro, J. Corren, I.D. Pavord, J. Maspero, S. Wenzel, K.F. Rabe, W.W. Busse, L. Ford, L. Sher, J.M. FitzGerald, C. Katelaris, Y. Tohda, B. Zhang, H. Staudinger, G. Pirozzi, N. Amin, M. Ruddy, B. Akinlade, A. Khan, J. Chao, R. Martincova, N.M.H. Graham, J.D. Hamilton, B.N. Swanson, N. Stahl, G.D. Yancopoulos, A. Teper, Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma, N. Engl. J. Med. 378 (26) (2018) 2486–2496.
- [4] E.R. Bleecker, J.M. FitzGerald, P. Chanez, A. Papi, S.F. Weinstein, P. Barker, S. Sproule, G. Gilmartin, M. Aurivillius, V. Werkström, M. Goldman, SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, Lancet 388 (10056) (2016) 2115–2127.
- [5] J.M. FitzGerald, E.R. Bleecker, P. Nair, S. Korn, K. Ohta, M. Lommatzsch, G.T. Ferguson, W.W. Busse, P. Barker, S. Sproule, G. Gilmartin, V. Werkström, M. Aurivillius, M. Goldman, CALIMA study investigators. Benralizumab, an antiinterleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet 388 (10056) (2016) 2128–2141.
- [6] H.G. Ortega, M.C. Liu, I.D. Pavord, G.G. Brusselle, J.M. FitzGerald, A. Chetta, M. Humbert, L.E. Katz, O.N. Keene, S.W. Yancey, P. Chanez, M.E.N.S.A. Investigators, Mepolizumab treatment in patients with severe eosinophilic asthma, N. Engl. J. Med. 371 (13) (2014) 1198–1207.
- [7] A. Dasgupta, M. Kjarsgaard, D. Capaldi, K. Radford, F. Aleman, C. Boylan, L.C. Altman, T.N. Wight, G. Parraga, P.M. O'Byrne, P. Nair, A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis, Eur. Respir. J. 49 (3) (2017), 1602486.
- [8] I.D. Pavord, P. Chanez, G.J. Criner, H.A.M. Kerstjens, S. Korn, N. Lugogo, J.B. Martinot, H. Sagara, F.C. Albers, E.S. Bradford, S.S. Harris, B. Mayer, D.B. Rubin, S.W. Yancey, F.C. Sciurba, Mepolizumab for eosinophilic chronic obstructive pulmonary disease, N. Engl. J. Med. 377 (17) (2017) 1613–1629.
- [9] C.E. Brightling, E.R. Bleecker, R.A. Panettieri Jr., M. Bafadhel, D. She, C.K. Ward, X. Xu, C. Birrell, R. van der Merwe, Benralizumab for chronic obstructive

pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebocontrolled, phase 2a study, Lancet Respir. Med. 2 (11) (2014) 891–901.

- [10] G.J. Criner, B.R. Celli, C.E. Brightling, A. Agusti, A. Papi, D. Singh, D.D. Sin, C.F. Vogelmeier, F.C. Sciurba, M. Bafadhel, V. Backer, M. Kato, A. Ramírez-Venegas, Y.F. Wei, L. Bjermer, V.H. Shih, M. Jison, S. O'Quinn, N. Makulova, P. Newbold, M. Goldman, U.J. Martin, GALATHEA and TERRANOVA study investigators. Benralizumab for the prevention of COPD exacerbations, N. Engl. J. Med. 381 (11) (2019) 1023–1034.
- [11] G.J. Criner, B.R. Celli, D. Singh, A. Agusti, A. Papi, M. Jison, N. Makulova, V.H. Shih, L. Brooks, P. Barker, U.J. Martin, P. Newbold, Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies, Lancet Respir. Med. 8 (2) (2020) 158–170.
- [12] P. Rogliani, M.G. Matera, E. Puxeddu, M. Mantero, F. Blasi, M. Cazzola, L. Calzetta, Emerging biological therapies for treating chronic obstructive pulmonary disease: a pairwise and network meta-analysis, Pulm. Pharmacol. Ther. 50 (2018) 28–37.
- [13] S.H. Lan, C.C. Lai, S.P. Chang, C.C. Hsu, C.H. Chen, Y.H. Wang, Y.L. Huang, C.Y. Wang, Y.S. Lin, Efficacy and safety of anti-interleukin-5 therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials, J. Microbiol. Immunol. Infect. (2020). S1684-1182(20)30253-X.
- [14] T. Donovan, S.J. Milan, R. Wang, E. Banchoff, P. Bradley, I. Crossingham, Anti-IL-5 therapies for chronic obstructive pulmonary disease, Cochrane Database Syst. Rev. 12 (2020) CD013432.
- [15] I.D. Pavord, K.R. Chapman, M. Bafadhel, F.C. Sciurba, E.S. Bradford, S. Schweiker Harris, B. Mayer, D.B. Rubin, S.W. Yancey, P. Paggiaro, Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO, Int. J. Chronic Obstr. Pulm. Dis. 16 (2021) 1755–1770.
- [16] C. Zhang, Y. Wang, M. Zhang, X. Su, T. Lei, H. Yu, J. Liu, Monoclonal antibodies targeting IL-5 or IL-5Ralpha in eosinophilic chronic obstructive pulmonary disease: a systematic review and meta-analysis, Front. Pharmacol. 12 (2021), 754268.
- [17] D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement, Open Med. 3 (3) (2009) e123–e130.
- [18] GRADE Working Group, Grading quality of evidence and strength of recommendations, BMJ 328 (7454) (2004) 1490.
- [19] S.S. Kon, J.L. Canavan, S.E. Jones, C.M. Nolan, A.L. Clark, M.J. Dickson, B.M. Haselden, M.I. Polkey, W.D. Man, Minimum clinically important difference for the COPD Assessment Test: a prospective analysis, Lancet Respir. Med. 2 (2014) 195–203.
- [20] Y.S. Punekar, S. Sharma, A. Pahwa, J. Takyar, I. Naya, P.W. Jones, Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis, Respir. Res. 18 (2017) 86.